MedCity News

JUNE 16, 2023

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.

Pharma 119

Pharma Food and Drug Administration Recruitment Pharmacology 119

PM360

NOVEMBER 29, 2022

Food and Drug Administration (FDA) or European Medicines Agency (EMA). Understanding patient sub-group exceptions for competitive or for label development purposes. Typically, a drug label refers to any information provided with prescription drugs, as requested by regulators such as the U.S. Challenges in Working with Label Data.

Food and Drug Administration 98

Food and Drug Administration Competition Safety Pharmacology 98

Legacy MEDSearch

OCTOBER 13, 2022

Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS) system. Senza HFX iQ is the first and only Artificial Intelligence-based SCS system that learns from patients. “Pain is variable from patient to patient and over time. Keith Grossman, Chairman and CEO of Nevro.

FDA 52

FDA Food and Drug Administration Recruitment Pharmacology 52

European Pharmaceutical Review

OCTOBER 19, 2022

The US Food and Drug Administration (FDA) has recently expressed concern to the US PTO about some types of innovator patent strategies that potentially delay generic entry into the market. 10 There is a fear that such practices discourage innovative approaches, impacting on patient welfare. CN202010111235.3A. 2020-02-24.

Food and Drug Administration 75

Food and Drug Administration Pharmaceutical products Pharmacology FDA 75

European Pharmaceutical Review

FEBRUARY 14, 2024

The first drug products to achieve biological licence approval (BLA) from the US Food and Drug Administration (FDA) are whole community products derived from human faecal matter and are indicted for Clostridium difficile infection. Firstly, the pharmacological response to LBPs does not follow traditional pharmacokinetic principles.

Food and Drug Administration 77

Food and Drug Administration Manufacturing Engineering Pharmacology 77

Evolve Your Success

OCTOBER 24, 2023

It might need to be something that allows it to be moved, bent, put over the patient, maneuvered through a hospital or a doctor’s office, or what have you to provide either additional functionality, transport, or whatever the case may be. I still want to be somehow attached to science, whether it’s working with patients, science, or doctors.

Sales 64

Sales Medical Manufacturing Medical sales 64

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 77

Food and Drug Administration Safety Patients Leads 77

pharmaphorum

JANUARY 23, 2023

It was a unique event, at which leaders from across the pharmaceutical pipeline addressed the needs of the industry, shared their own insights, and tackled debates on the crucial topics that influence the future of patient outcomes. Their family can only afford junk food, [they] have been raised on junk food.

Pharma 78

Pharma Food Pharmacology Medicine 78

Pharmaceutical Technology

AUGUST 8, 2022

In 2017, the US Food and Drug Administration (FDA) broke ground by approving the first drug with an embedded biosensor to track its use. Proteus Health’s Abilify MyCite had an ingestible sensor that could track if a patient consumed the drug. You don’t want to use this to stigmatize patients or to ‘catch them lying.’

Food and Drug Administration 122

Food and Drug Administration FDA Medicine Patients 122

Pharmaceutical Technology

FEBRUARY 13, 2023

As well as presenting an acceptable PK profile and demonstrating in-vivo efficacy, it becomes important to show that the candidate drug has a good safety pharmacology margin with an acceptable drug-drug interaction (DDI) profile.

Food and Drug Administration 52

Food and Drug Administration Leads Pharmaceutical Pharmaceutical research 52